3. Subjects with diagnosis of HER2-negative breast cancer that was confirmed by IHC or ISH assessment of tumor samples (from primary or metastatic site) in any of the following cases. (If metastasis is confirmed and it is feasible to obtain the tumor sample from the metastatic site, HER2 status assessment must be performed using the sample from the metastatic site).